摘要
由冠状动脉阻塞所致的缺血性心脏病在临床上较为常见 ,经皮冠状动脉腔内成形术 (PTCA)是冠心病的主要治疗手段之一。冠状动脉内支架植入术是在 PTCA基础上发展起来的介入技术 ,其应用在很大程度上提高了介入技术对于血管病变的临床价值。但无论是 PTCA还是冠脉内支架植入术均面临着急性血管闭塞和再狭窄的难题 ,特别是冠状动脉内支架植入术显著激活血小板而增加了亚急性支架血栓形成的风险。目前 ,主要预防措施是应用抗血小板和抗凝药物治疗以减少血栓形成 ,针对这两大类药物的研究报道很多 ,本文主要对其在药理学 ,预防血栓形成及再狭窄的疗效 。
Ischemic heart disease due to coronary obstruction is very common in clinical practice.Percutaneous transluminal coronary angioplasty(PTCA)is one of the major approaches to treat coronary heart disease.Based on PTCA developed the therapy of intracoronary stent implantation.Its clinical application has greatly improved the status of the interventional technique.But both PTCA and stent implantation are confronted with the problems of acute occlusion and restenosis,especially the intracoronary stent implantation can significantly activate platelets and consequently increase the risk of subacute stent thrombosis.The major current preventive measure is to use antiplatelet or anticoagulant drugs.There have been many reports on these two kinds of drugs.Their pharmacology,curative effects in preventing thrombosis and restenosis as well as their adverse effects are briefly discussed in this review.
出处
《心血管病学进展》
CAS
2000年第5期285-289,共5页
Advances in Cardiovascular Diseases
关键词
冠心病
冠状动脉内支架植入术
抗血小板药
antiplatelet,anticoagulatant,Percutaneous transluminal coronary angioplasty,intracoronary stent implantation,stent thrombosis,restenosis.
